This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, K. H. Articles by Muto, M. G. Search for Related Content PubMed PubMed Citation Articles by Lu, K. H. Articles by Muto, M. G. Social Bookmarking                            What's this?

Occult Ovarian Tumors in Women With BRCA1 or BRCA2 Mutations Undergoing Prophylactic Oophorectomy

From the Familial Ovarian Cancer Center, Cancer Risk and Prevention Program, Division of Cancer Epidemiology and Control, Gillette Center for Women’s Cancers, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, and Department of Pathology, Brigham and Women’s Hospital; and Division of Gynecologic Oncology, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA.

Address reprint requests to Karen H. Lu, MD, Department of Gynecologic Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 67, Houston, TX 77030-4095; email khlu{at}mdanderson.org

PURPOSE: To review the findings at prophylactic oophorectomy of a series of women who presented to a familial breast and ovarian cancer clinic.

MATERIALS AND METHODS: Data from medical charts, operative notes, and pathology reports were collected on women who had undergone prophylactic oophorectomies because of the elevated risk of ovarian cancer. Because only a subset of patients underwent BRCA1 and BRCA2 testing, each patient’s risk of hereditary predisposition was calculated using the Berry-Parmigiani model and family history data.

RESULTS: From June 1989 to December 1998, 50 women seen at our clinic underwent prophylactic oophorectomy, 33 of whom had a calculated risk of carrying a germline BRCA1 or BRCA2 mutation greater than 25%. Among this group, four incidental tumors were found (four of 33, or 12%); one tumor was noted at the time of surgery and three were noted only in the final pathology. Two patients had microscopic, poorly differentiated serous adenocarcinomas in multiple sites on both ovaries. A third patient had a bilateral serous borderline tumor with micropapillary features. The fourth patient had a microscopic serous borderline ovarian tumor. All four patients had germline BRCA1 or BRCA2 mutations, and three had unremarkable transvaginal ultrasonography examinations within 6 months before prophylactic surgery.

CONCLUSION: Foci of malignant tumor are not uncommon in prophylactic oophorectomies performed in women at very high risk for ovarian cancer and may not be detected on ultrasonograms. Surgeons should have a high suspicion of finding cancer in these women at the time of prophylactic surgery, and careful pathologic assessment of the specimens should be conducted.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Levanon, C. Crum, and R. Drapkin New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293. [Abstract] [Full Text] [PDF]

				M. H. Greene, M. Piedmonte, D. Alberts, M. Gail, M. Hensley, Z. Miner, P. L. Mai, J. Loud, G. Rodriguez, J. Basil, et al. A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 594 - 604. [Abstract] [Full Text] [PDF]

				M. J. Callahan, C. P. Crum, F. Medeiros, D. W. Kindelberger, J. A. Elvin, J. E. Garber, C. M. Feltmate, R. S. Berkowitz, and M. G. Muto Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction J. Clin. Oncol., September 1, 2007; 25(25): 3985 - 3990. [Abstract] [Full Text] [PDF]

				N. D. Kauff and R. R. Barakat Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2 J. Clin. Oncol., July 10, 2007; 25(20): 2921 - 2927. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes J. Clin. Oncol., October 1, 2006; 24(28): 4642 - 4660. [Abstract] [Full Text] [PDF]

				M. A. Brewer, J. Ranger-Moore, A. Baruche, D. S. Alberts, M. Greene, D. Thompson, Y. Liu, J. Davis, and P. H. Bartels Exploratory Study of Ovarian Intraepithelial Neoplasia Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 299 - 305. [Abstract] [Full Text] [PDF]

				C. B. Powell, E. Kenley, L.-m. Chen, B. Crawford, J. McLennan, C. Zaloudek, M. Komaromy, M. Beattie, and J. Ziegler Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers: Role of Serial Sectioning in the Detection of Occult Malignancy J. Clin. Oncol., January 1, 2005; 23(1): 127 - 132. [Abstract] [Full Text] [PDF]

				R. Hogg and M. Friedlander Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk J. Clin. Oncol., April 1, 2004; 22(7): 1315 - 1327. [Abstract] [Full Text] [PDF]

				M. A. Brewer, K. Johnson, M. Follen, D. Gershenson, and R. Bast Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res., January 1, 2003; 9(1): 20 - 30. [Abstract] [Full Text] [PDF]

				T. UDAGAWA, A. FERNANDEZ, E.-G. ACHILLES, J. FOLKMAN, and R. J. D'AMATO Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy FASEB J, September 1, 2002; 16(11): 1361 - 1370. [Abstract] [Full Text] [PDF]

				A. DeMichele and B. L. Weber Risk Management in BRCA1 and BRCA2 Mutation Carriers: Lessons Learned, Challenges Posed J. Clin. Oncol., March 1, 2002; 20(5): 1164 - 1166. [Full Text] [PDF]

				L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd, P. Borgen, et al. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers J. Clin. Oncol., March 1, 2002; 20(5): 1260 - 1268. [Abstract] [Full Text] [PDF]

				M. Brewer, U. Utzinger, W. Satterfield, L. Hill, D. Gershenson, R. Bast, J. T. Wharton, R. Richards-Kortum, and M. Follen Biomarker Modulation in a Nonhuman Rhesus Primate Model for Ovarian Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., August 1, 2001; 10(8): 889 - 893. [Abstract] [Full Text] [PDF]

				J. N. Weitzel and L. E. McCahill The Power of Genetics to Target Surgical Prevention N. Engl. J. Med., June 21, 2001; 344(25): 1942 - 1944. [Full Text] [PDF]